MARKET

CDAK

CDAK

Codiak BioSciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.50
-1.19
-6.73%
Opening 13:51 02/26 EST
OPEN
18.05
PREV CLOSE
17.69
HIGH
18.28
LOW
16.20
VOLUME
98.18K
TURNOVER
--
52 WEEK HIGH
37.85
52 WEEK LOW
7.90
MARKET CAP
306.80M
P/E (TTM)
-16.8677
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
, /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised in Series B financing. The round included contributions from funds and accoun...
PR Newswire - PRF · 1d ago
Independent Director Briggs Morrison Just Bought A Handful Of Shares In Codiak BioSciences, Inc. (NASDAQ:CDAK)
Whilst it may not be a huge deal, we thought it was good to see that the Codiak BioSciences, Inc. ( NASDAQ:CDAK...
Simply Wall St. · 6d ago
Codiak closes $66.4M capital raise
Codiak BioSciences (CDAK) announces the closing of its previously announced underwritten public offering of an aggregate of 3M shares at a price of $21/share with expected gross proceeds of $66.4M.The
Seekingalpha · 02/17 21:35
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters Option
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announ...
GlobeNewswire · 02/17 21:30
Codiak Priced 2.75M Share Public Offering of Common Stock @$21/Share
Codiak BioSciences, Inc. (NASDAQ: CDAK) announced the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting un...
Benzinga · 02/12 10:56
Codiak prices equity offering at $21
Codiak BioSciences (CDAK) has priced its public offering of 2.75M common shares at $21.00/share, for gross proceeds of ~$57.8M.Underwriters' over-allotment is an additional 412.5K shares.Closing date is February 17.Shares up 2% premarket.
Seekingalpha · 02/12 10:37
Goldman Sachs & Co., Evercore ISI, William Blair Acting as Bookrunning Managers for Codiak Offering >CDAK
Goldman Sachs & Co., Evercore ISI, William Blair Acting as Bookrunning Managers for Codiak Offering >CDAK
Dow Jones · 02/12 03:38
Codiak BioSciences Offering Expected to Close Feb. 17 >CDAK
Codiak BioSciences Offering Expected to Close Feb. 17 >CDAK
Dow Jones · 02/12 03:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDAK. Analyze the recent business situations of Codiak BioSciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDAK stock price target is 35.00 with a high estimate of 45.00 and a low estimate of 29.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 9.79M
% Owned: 52.66%
Shares Outstanding: 18.59M
TypeInstitutionsShares
Increased
0
0
New
47
9.79M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.06%
Pharmaceuticals & Medical Research
-0.77%
Key Executives
Chairman/Director
Steven Gillis
President/Chief Executive Officer/Director
Douglas Williams
Chief Financial Officer/Primary Contact
Linda Bain
Executive Officer
Ariel Jasie
Executive Officer
Jan Lotvall
  • Dividends
  • Splits
  • Insider Activity
No Data
About CDAK
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).

Webull offers kinds of Codiak BioSciences Inc stock information, including NASDAQ:CDAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDAK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDAK stock methods without spending real money on the virtual paper trading platform.